| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6099286 | Journal of Crohn's and Colitis | 2014 | 9 Pages |
Abstract
Infliximab treatment has beneficial clinical effect which is confirmed by decrease of PCDAI and increase of IMPACT-III. Autoregressive regression analysis showed regression relation between IMPACT-III and PCDAI and laboratory parameters.
Keywords
QOLARCLNNFIRMSEAPCDAITLIIFXCFIIBDAutoregressive cross-lagged modelMLRQuality of lifeχ2PediatricInfliximabCrohn's diseaseInflammatory bowel diseaseRoot mean square error of approximationTucker–Lewis indexnon-normed fit indexPediatric Crohn's Disease Activity IndexComparative Fit IndexSEMStructural equation modelingdegree of freedomC-reactive proteinCRPChi-squareUlcerative colitis
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Dolóresz Szabó, Gyöngyi Kökönyei, András Arató, Antal DezsÅfi, Kriszta Molnár, Katalin Eszter Müller, Péter László Lakatos, Mária Papp, Barbara D. Lovász, Petra A. Golovics, Áron Cseh, Gábor Veres,